Shares of Kite Pharma Inc. (NASDAQ:KITE) were up 4.9% during trading on Wednesday . The company traded as high as $58.74 and last traded at $58.71, with a volume of 363,156 shares. The stock had previously closed at $55.98.

KITE has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Kite Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. Jefferies Group restated a “buy” rating and set a $75.00 target price on shares of Kite Pharma in a research report on Monday, April 18th. Stifel Nicolaus restated a “buy” rating and set a $63.00 target price on shares of Kite Pharma in a research report on Tuesday, April 19th. Mizuho restated a “buy” rating and set a $90.00 target price on shares of Kite Pharma in a research report on Thursday, April 21st. Finally, Maxim Group restated a “buy” rating on shares of Kite Pharma in a research report on Wednesday, April 20th. Two research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $74.11.

The company’s market cap is $2.89 billion. The company has a 50-day moving average of $51.46 and a 200-day moving average of $48.79.

Kite Pharma (NASDAQ:KITE) last announced its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.60) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.08) by $0.48. During the same period in the previous year, the business earned ($0.36) earnings per share. The company earned $5.10 million during the quarter, compared to analysts’ expectations of $4.61 million. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. On average, analysts expect that Kite Pharma Inc. will post ($5.60) EPS for the current fiscal year.

In related news, SVP Jeffrey Wiezorek sold 3,000 shares of the stock in a transaction that occurred on Wednesday, June 1st. The shares were sold at an average price of $50.65, for a total value of $151,950.00. Following the transaction, the senior vice president now owns 16,367 shares in the company, valued at approximately $828,988.55. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Cynthia M. Butitta sold 20,000 shares of the stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $50.71, for a total transaction of $1,014,200.00. Following the completion of the transaction, the chief operating officer now owns 105,401 shares in the company, valued at approximately $5,344,884.71. The disclosure for this sale can be found here.

Several large investors have recently modified their holdings of KITE. Mutual of America Capital Management LLC boosted its stake in shares of Kite Pharma by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 16,336 shares of the biopharmaceutical company’s stock worth $1,007,000 after buying an additional 95 shares during the last quarter. Morgan Stanley boosted its stake in shares of Kite Pharma by 3.5% in the fourth quarter. Morgan Stanley now owns 21,628 shares of the biopharmaceutical company’s stock worth $1,332,000 after buying an additional 739 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Kite Pharma by 10.2% in the fourth quarter. Rhumbline Advisers now owns 28,768 shares of the biopharmaceutical company’s stock worth $1,773,000 after buying an additional 2,660 shares during the last quarter. GAM Holding AG boosted its stake in shares of Kite Pharma by 275.3% in the fourth quarter. GAM Holding AG now owns 30,400 shares of the biopharmaceutical company’s stock worth $1,873,000 after buying an additional 22,300 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Kite Pharma during the fourth quarter worth approximately $2,088,000.

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.